Comparative Effects of Staphylokinase and Alteplase in Rabbit Bleeding Time Models

Summary

Background: The pathogenesis of bleeding associated with thrombolytic therapy remains largely unknown, although spontaneous bleeding appears to correlate with bleeding time prolongation. Here, the comparative effects on cuticle bleeding times (CBT) and ear puncture bleeding times (EBT) of recombinant staphylokinase (Sak) and alteplase (recombinant tissue-type plasminogen activator, rt-PA) at equivalent doses, alone and in combination with aspirin and heparin, were studied in rabbits.

Methods and Results: Groups of 4 to 9 rabbits were allocated to one of the 8 following intravenous infusions: saline; aspirin 15 mg/kg and heparin - 100 IU/kg bolus and 10 IU/kg infusion over one hour; 1.5 mg/kg rt-PA; 1.5 mg/kg rt-PA plus aspirin and heparin; 4.5 mg/kg rt-PA; 0.5 mg/kg Sak; 0.5 mg/kg Sak plus aspirin and heparin and 1.5 mg/kg Sak. Bleeding times were determined 30 and 15 min before and 5,15,30 and 60 min after the administration over one min of saline, rt-PA or Sak, by simultaneously severing a nail cuticle (CBT) and by puncturing the ear (EBT). Bleeding times were unaffected by saline and by both doses of Sak in monotherapy. Heparin-aspirin and low dose rt-PA significantly lengthened EBT but not CBT. Both CBT and EBT were significantly prolonged (to a mean of >4 times pretreatment at 5 min) after high-dose rt-PA and after the combined administration of heparin and aspirin with either Sak or rt-PA. rt-PA provoked significantly longer bleeding than Sak in the CBT (p = 0.001; mean estimated difference = 23 min), but not in the EBT. rt-PA but not Sak degraded plasma fibrinogen dose-dependently. CBT correlated inversely with fibrinogen (r = −0.66, p = 0.001) but EBT did not.

Conclusions: At equivalent doses Sak displays a significantly higher fibrin specificity and prolongs bleeding time less than rt-PA, particularly in the nail cuticle bleeding time model in which larger vessels are injured that require fibrinogen for hemostasis.

• References

• 1 Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989; 111: 1010-1022
• 2 Levine MN, Goldhaber SZ, Gore JM, Hirsh J, Califf RM. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1995; 108: 291S-301S
• 3 Marder VJ, Hirsh J, Bell WRM. Rationale and practical basis of thrombolytic therapy. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, Third Edition Colman RW, March J, Marder VJ, Salzman EW. eds JB Lippincott Company; Philadelphia: 1994: 1514-1533 (Chapter 79)
• 4 Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TC. Terrin ML for the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) Trial – Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11
• 5 Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential. Blood 1994; 84: 680-686
• 6 Vanderschueren S, Barrios L, Kerdsinchai P, Van den HeuvelP, Hermans L, Vrolix M, De ManF, Benit E, Muyldermans L, Collen D, Van de WerfF. for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-2049
• 7 Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Vermylen J, Collen D. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995; 92: 2050-2057
• 8 Garabedian HD, Gold HK, Leinbach RC, Svizzero TA, Finkelstein DM, Guerrero JL, Collen D. Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin. J Am Coll Cardiol 1991; 17: 1213-1222
• 9 Vaughan DE, Declerck PJ, De MolM, Collen D. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. J Clin Invest 1989; 84: 586-591
• 10 Gimple LW, Gold HK, Leinbach MC, Coller BS, Werner W, Yasuda T, Johns JA, Ziskind AA, Finkelstein D, Collen D. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 80: 581-588
• 11 Schlott B, Hartmann M, Giihrs K-H, Birch-Hirschfeid E, Pohl H-D, Vanderschueren S, Van de WerfF, Michoel A, Collen D, Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Bio/Technology 1994; 12: 185-189
• 12 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-1084
• 13 Jang I-K, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustaines arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990; 67: 1552-1561
• 14 Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 1991; 84: 1216-1234
• 15 Lijnen HR, Stassen JM, Vanlinthout I, Fukao H, Okada K, Matsuo O, Collen D. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemost 1991; 66: 458-473
• 16 Vanderschueren S, Collen D, Van de WerfF. A pilot study on bolus admin-stration of recombinant staphylokinase for coronary artery thrombolysis. Submitted
• 17 Mellott MJ, Ramjit DR, Stabilito II, Hare TR, Senderak ET, Lynch JR, Gardell SJ. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model. Thromb Haemost 1995; 73: 478-483
• 18 Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue-type plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-1544
• 19 Marder VJ, Shortell CK, Fitzpatrick PG, Kim C, Oxley D. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. Thromb Res 1992; 67: 31-40
• 20 Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van DomburgR, Boersma E, Franzosi MG, Califf R, Schroder R, Braun-wald E. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523-1528
• 21 Sloan MA, Price TR, Petito CK, Randall AMY, Solomon RE, Terrin ML, Gore J, Collen D, Kleiman N, Feit F, Babb J, Herman M, Roberts WC, Sopko G, Bovill E, Forman S. Knatterud GL, for the TIMI Investigators. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 1995; 45: 649-658